Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
The University of Texas Health Science Center at San Antonio · Audie L. Murphy Memorial VA Hospital · +2 more institutions
Abstract
The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited.
To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM.
Citation impact
- FWCI
- 62.49
- Percentile
- 100%
- References
- 63
Authors
12- KCKenneth CusiCorresponding
The University of Texas Health Science Center at San Antonio, Audie L. Murphy Memorial VA Hospital, Murphy Oil Corporation (United States), Malcom Randall VA Medical Center
- BOBeverly Orsak
The University of Texas Health Science Center at San Antonio, Audie L. Murphy Memorial VA Hospital, Murphy Oil Corporation (United States), Malcom Randall VA Medical Center
- FBFernando Bril
The University of Texas Health Science Center at San Antonio, Audie L. Murphy Memorial VA Hospital, Murphy Oil Corporation (United States), Malcom Randall VA Medical Center
- RLRomina Lomonaco
The University of Texas Health Science Center at San Antonio, Audie L. Murphy Memorial VA Hospital, Murphy Oil Corporation (United States), Malcom Randall VA Medical Center
- JHJoan Hecht
The University of Texas Health Science Center at San Antonio, Audie L. Murphy Memorial VA Hospital, Murphy Oil Corporation (United States), Malcom Randall VA Medical Center
Topics & keywords
- Pioglitazone
- Medicine
- Prediabetes
- Internal medicine
- Gastroenterology
- Nonalcoholic fatty liver disease
- Population
- Type 2 Diabetes Mellitus
- Good health and well-being